WebbOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, … Webb11 apr. 2024 · Currently, records show that 184.00 million of the company’s shares remain outstanding. The insiders hold 0.20% of outstanding shares, whereas institutions hold 97.20%. The stats also highlight that short interest as of Mar 14, 2024, stood at 8.99 million shares, resulting in a short ratio of 0.41 at that time.
Ocugen Highlights Interim Data From Gene Therapy Study For …
WebbOCGN Stock : USD 0.81 0.06 8.00% : Ocugen Inc stock price prediction is an act of determining the future value of Ocugen shares using few different conventional methods such as EPS estimation, analyst consensus, ... Shares Short Prior … Webbför 11 timmar sedan · Ocugen Inc OCGN announced preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of the Phase 1/2 trial of OCU400 for RP associated with NR2E3 and Rhodopsin ... china yuan dollar exchange rate
ALL OCGN SHARES AVAILABLE TO SHORT ARE TAKEN.
WebbMission Statement. The mission of ShortSqueeze® is to provide short interest stock market data and services, so our members will be better informed of short selling in the … Webb23 feb. 2024 · Technically, shares are challenging their 50% retracement level for a second time after backtracking from Ocugen’s Feb. 8 moonshot reaction as investors learned of the company’s definitive... Webbför 2 dagar sedan · MALVERN - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host an Investor and Analyst Event on April 14, 2024, at 8 a.m. ET. During the webcast and … china yuan to php